Press Releases

 
Press Releases
  Date Title View
Sep 21, 2017
BRISBANE, Calif.--(BUSINESS WIRE)-- Innoviva, Inc. (NASDAQ: INVA) today announced that Michael W. Aguiar, Innoviva's President and Chief Executive Officer and Eric d'Esparbes, SVP and Chief Financial Officer will present at the Cantor Fitzgerald Global Healthcare Conference on Tuesday, September 26 at 4:35 ...
Sep 20, 2017
Trelegy Ellipta met study primary endpoint demonstrating reduction in exacerbations compared with the dual therapies Anoro Ellipta and Relvar/Breo Ellipta in patients with COPD LONDON--(BUSINESS WIRE)-- GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today anno...
Sep 18, 2017
LONDON--(BUSINESS WIRE)-- GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the US Food and Drug Administration (FDA) has approved once-daily, single inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI), under the brand name Trelegy Elli...
Sep 15, 2017
LONDON--(BUSINESS WIRE)-- GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending marketing authorisation for fluticasone furoate/ umec...
Sep 11, 2017
Relvar Ellipta was superior to usual care treatment in improving asthma control for patients in Salford Lung Study. LONDON & BRISBANE, Calif.--(BUSINESS WIRE)-- GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced positive results from the Salford Lung Study ...
Sep 7, 2017
BRISBANE, Calif.--(BUSINESS WIRE)-- Innoviva, Inc. (NASDAQ: INVA) today announced that Michael W. Aguiar, Innoviva's President and Chief Executive Officer, will present in a fireside chat format discussion at the Morgan Stanley 15th Annual Global Healthcare Conference at the Grand Hyatt Hotel in New York, NY, ...
Aug 30, 2017
BRISBANE, Calif.--(BUSINESS WIRE)-- Innoviva, Inc. (NASDAQ: INVA) today announced that Michael W. Aguiar, Innoviva's President and Chief Executive Officer and Eric d'Esparbes, the Company's Senior Vice President and Chief Financial Officer will participate in the 2017 Baird Global Healthcare Conference a...
Aug 21, 2017
Closes $250 Million Term B Loan Refinancing plan expected to reduce the associated current cash interest expense by nearly one-half BRISBANE, Calif.--(BUSINESS WIRE)-- Innoviva, Inc. ("Innoviva" or the "Company") (NASDAQ: INVA) today announced the closing of a $250 m...
Aug 7, 2017
BRISBANE, Calif.--(BUSINESS WIRE)-- Innoviva, Inc. (NASDAQ: INVA) (the "Company" or "Innoviva") today announced that it closed its offering of the Company's 2.50% convertible senior notes due 2025 (the "Notes") for gross proceeds of $192.5 million in aggregate principal. The proceeds include the Notes sold pursua...
Aug 1, 2017
BRISBANE, Calif.--(BUSINESS WIRE)-- Innoviva, Inc. (NASDAQ: INVA) (the "Company" or "Innoviva") today announced the pricing of $175 million aggregate principal amount of the Company's 2.50% convertible senior notes due 2025 (the "Notes"). The Notes will be sold in a private placement to qualified institutional ...
1
...
NextLast
= add release to Briefcase

Innoviva NASDAQ: INVA

$13.78 0.29 (2.15%) 09/22/17 4:00 PM ET Refresh Quote

Data provided by Nasdaq.
Minimum 15 minutes delayed.

Contact

Innoviva Investor Relations & Media
650.238.9640

For business development inquiries,
please contact bd@inva.com.